1 Top Biotech Stock Ready for a Bull Run
The road to FDA approval can be long, and in the case of COVID-19 vaccines, there is no time for delays and no room for error. One company that has come to understand this very well is Novavax (NASDAQ: NVAX). Since 2020, the company has been developing a vaccine to help prevent and fight the impact of COVID-19. Now, after a year of declining confidence from the market, the company's awaiting judgment from the FDA -- leaving investors wondering what the agency will say, and how that might affect the company's shares.
Image Source: Getty Images
Novavax has worked tirelessly to develop a successful COVID-19 vaccine candidate. But after manufacturing delays led the company to miss deadlines, it's still trying to prove that its Nuvaxovid's 90% efficacy rate and 100% protection against moderate and severe disease levels is worthy of FDA approval. The company also touts the vaccine's convenience for doctors; it doesn't have to be frozen, making it easier to store and transport.
Source Fool.com
